Participants
| Role | Name | HCID | Charge |
|---|
| Reactant | Triethylamine | HCID 8471 | — |
| Reactant | HOAt | HCID 181649 | — |
| Reactant | Methanaminium, N-((dimethylamino)(3H-1,2,3-triazolo(4,5-b)pyridin-3-yloxy)methylene)-N-methyl-, hexafluorophosphate(1-) (1:1) | HCID 9886157 | — |
| Reactant | HCID 58430990 | HCID 58430990 | — |
| Reactant | HCID 58431091 | HCID 58431091 | — |
| Solvent | Dimethylformamide | HCID 6228 | — |
| Product | HCID 58431203 | HCID 58431203 | 72.6% |
Reaction Steps
To a solution of (S)-2-{[(R)-5-(4-cyano-benzyl)-7-(3,5-dichloro-phenyl)-5-methyl-6-oxo-6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-carbonyl]-amino}-propionic acid (60 mg, 0.117 mmol) and (R)-3-(2H-tetrazol-5-yl)-piperidine (35.8 mg, 0.234 mmol) in anhydrous DMF (1 mL) was added Et3N (33.8 μl, 0.234 mmol) at 0° C. HOAt (47.8 mg, 0.351 mmol) was then added to the reaction. After 10 min of stirring at 0° C., HATU (53.4 mg, 0.140 mmol) was added. The reaction was slowly warmed to 25° C. and stirred overnight. The crude reaction was purified by reverse phase HPLC to afford 55 mg of (3R)-3-(4-cyanobenzyl)-1-(3,5-dichlorophenyl)-3-methyl-N-{(1S)-1-methyl-2-oxo-2-[(3R)-3-(2H-tetrazol-5-yl)piperidin-1-yl]ethyl}-2-oxo-2,3-dihydro-1H-imidazo[1,2-a]imidazole-5-carboxamide as a white solid, m/z 647.5 [M+1]+.
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| Patent number | US08552205B2 |
|---|
| Source dataset | uspto-grants-2013_10 |
|---|
| ORD ID | ord-397da7ec98cb47b1bc8bd458733a8da2 |
|---|
| Source note | uspto-grants-2013_10 |
|---|